參考文獻
Supreme Court of the United States, Helsinn Healthcare S.A v. Teva Pharmaceuticals USA, Inc., available at: https://www.supremecourt.gov/opinions/18pdf/17-1229_2co3.pdf (last visited Feb. 9, 2019).
我國專利法第22條
Benson, Robert J..Development & Trends: U.S. Patent Litigation & PTAB Practice.Annual Global Innovation Conference: Practical Guidance in IP, Antitrust, Trade, and Business for Taiwanese Companies.(Annual Global Innovation Conference: Practical Guidance in IP, Antitrust, Trade, and Business for Taiwanese Companies).
Gene Quinn & Steve Brachmann, Industry Reaction to Helsinn Healthcare v. Teva Pharmaceuticals Oral Arguments (2018/12/13), IP Watchdog, http://www.ipwatchdog.com/2018/12/13/industry-reaction-helsinn-healthcare-v-teva-pharmaceuticals-oralargument/id=104009/ (last visited Feb. 9, 2019).
Kevin E. Noonan, Helsinn Healthcare S. A. v. Teva Pharmaceuticals USA, Inc. (2019), Patent Docs, https://www.patentdocs.org/2019/01/helsinn-healthcare-s-a-v-teva-pharmaceuticals-usa-inc-2019.html (last visited Feb. 9, 2019).
延伸閱讀
- 陳志軒（2022）。COVID-19疫苗接種保障保險之研究〔碩士論文，淡江大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0002-2107202200025200
- 吳家雯（2005）。全民健康保險研究資料庫HMG-CoA Reductase Inhibitors處方型態及用藥安全性分析：自藥品交互作用觀點探討〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2005.02195
- 李宗儒（2020）。英國資訊專員辦公室發布關於COVID-19接觸史追蹤應用程式之個人資料保護期望。科技法律透析，32(12)，4-6。https://www.airitilibrary.com/Article/Detail?DocID=a0000571-202012-202102260008-202102260008-4-6
- Yao, C. Y. (2022). COVID-19必要醫療貨品出口限制措施所涉WTO法律問題之研究 [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU202203938
- 陳玉峯（2017）。外來種入侵步步進逼，「有效」防禦系統何時建立 銀膠菊的遺憾。生態台灣，(55)，43-51。https://www.airitilibrary.com/Article/Detail?DocID=19914903-201704-201704190017-201704190017-43-51